Cargando…

Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation

Detalles Bibliográficos
Autores principales:	Maher, Toby M., Lancaster, Lisa H., Jouneau, Stéphane, Morrison, Lake, Lederer, David J., Molina-Molina, Maria, Bendstrup, Elisabeth, Kirchgaessler, Klaus-Uwe, Gilberg, Frank, Axmann, Judit, Petzinger, Ute, Noble, Paul W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2019
Materias:	Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6600834/ https://www.ncbi.nlm.nih.gov/pubmed/30950636 http://dx.doi.org/10.1513/AnnalsATS.201810-720RL

Ejemplares similares

Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis
por: Costabel, Ulrich, et al.
Publicado: (2019)

Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis
por: Glassberg, Marilyn K., et al.
Publicado: (2019)

Pirfenidone in Unclassifiable Interstitial Lung Disease: A Subgroup Analysis by Concomitant Mycophenolate Mofetil and/or Previous Corticosteroid Use
por: Kreuter, Michael, et al.
Publicado: (2021)

Efficacy of Pirfenidone vs. Placebo in Unclassifiable Interstitial Lung Disease, by Surgical Lung Biopsy Status: Data From a post-hoc Analysis
por: Molina-Molina, Maria, et al.
Publicado: (2022)

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial
por: Maher, Toby M, et al.
Publicado: (2018)

Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials
por: Nathan, Steven D, et al.
Publicado: (2018)

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis
por: Flaherty, Kevin R., et al.
Publicado: (2018)

Unmet needs in the treatment of idiopathic pulmonary fibrosis―insights from patient chart review in five European countries
por: Maher, Toby M., et al.
Publicado: (2017)

Pirfenidone treatment in idiopathic pulmonary fibrosis: nationwide Danish results
por: Salih, Goran Nadir, et al.
Publicado: (2016)

Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events
por: Costabel, Ulrich, et al.
Publicado: (2014)

Patients’ and Healthcare Professionals’ Experiences of Idiopathic Pulmonary Fibrosis Treatment with the Pirfenidone 801 mg Tablet Formulation: A Multinational Survey
por: Lancaster, Lisa H., et al.
Publicado: (2020)

Erratum to: Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events
por: Costabel, Ulrich, et al.
Publicado: (2014)

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
por: Lancaster, Lisa H., et al.
Publicado: (2017)

Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis
por: Cottin, Vincent, et al.
Publicado: (2015)

No effect of pirfenidone treatment in fulminant bleomycin-induced pneumonitis
por: Bendstrup, Elisabeth, et al.
Publicado: (2014)

A review of the challenges, learnings and future directions of home handheld spirometry in interstitial lung disease
por: Maher, Toby M., et al.
Publicado: (2022)

Pirfenidone treatment of idiopathic pulmonary fibrosis
por: Gan, Ye, et al.
Publicado: (2011)

Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study
por: Cottin, Vincent, et al.
Publicado: (2018)

Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis: Experience from 92 Sites in an Open-Label US Expanded Access Program
por: Lancaster, Lisa, et al.
Publicado: (2017)

The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis
por: Cottin, Vincent
Publicado: (2013)

An Open-Label, Phase II Study of the Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (PIPF-002)
por: Gotfried, Mark H., et al.
Publicado: (2018)

Disease Behaviour During the Peri-Diagnostic Period in Patients with Suspected Interstitial Lung Disease: The STARLINER Study
por: Wijsenbeek, Marlies S., et al.
Publicado: (2021)

Gastrointestinal pirfenidone adverse events in idiopathic pulmonary fibrosis depending on diet: the MADIET clinical trial
por: Molina-Molina, Maria, et al.
Publicado: (2023)

Efficacy and Safety of Pirfenidone in Advanced Versus Non-Advanced Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Six Clinical Studies
por: Behr, Jürgen, et al.
Publicado: (2023)

Design of a Study Assessing Disease Behaviour During the Peri-Diagnostic Period in Patients with Interstitial Lung Disease: The STARLINER Study
por: Wijsenbeek, Marlies, et al.
Publicado: (2018)

Pirfenidone treatment in idiopathic pulmonary fibrosis: A Saudi experience
por: Alhamad, Esam H.
Publicado: (2015)

Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials
por: Noble, Paul W., et al.
Publicado: (2016)

Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials
por: Lancaster, Lisa, et al.
Publicado: (2016)

Weight loss and outcomes in subjects with progressive pulmonary fibrosis: data from the INBUILD trial
por: Kreuter, Michael, et al.
Publicado: (2023)

Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond
por: Aimo, Alberto, et al.
Publicado: (2022)

Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis
por: Kreuter, Michael, et al.
Publicado: (2017)

Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis
por: Nathan, Steven D, et al.
Publicado: (2016)

Updated Evaluation of the Safety, Efficacy and Tolerability of Pirfenidone in the Treatment of Idiopathic Pulmonary Fibrosis
por: Gulati, Swati, et al.
Publicado: (2020)

Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis
por: Takeda, Yoshito, et al.
Publicado: (2014)

Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis
por: Valeyre, Dominique, et al.
Publicado: (2014)

Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy
por: Margaritopoulos, George A, et al.
Publicado: (2016)

Global incidence and prevalence of idiopathic pulmonary fibrosis
por: Maher, Toby M., et al.
Publicado: (2021)

Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis
por: Kreuter, Michael, et al.
Publicado: (2021)

The treatment of idiopathic pulmonary fibrosis
por: Woodcock, Hannah V., et al.
Publicado: (2014)

Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis
por: van Manen, Mirjam J.G., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_l6oqcben9mnatubcmn6ojaklj7